Clinical Trials Search
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery.
Part A and B: The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and MTD of BMS-986016 administered alone and in combination with nivolumab in subjects with advanced solid tumors. Part A1:The primary objective of BMS-986016 monotherapy cohort expansion is to gather additional safety,tolerability, and preliminary efficacy information of BMS-986016 monotherapy.
BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); BMS-986213 (); Nivolumab ()